secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001764013-23-000090
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports Q1 net loss of $73.9M; IMVT-1402 Phase 1 data on track for September 2023
--------------------------------------------------------------------------------

- Net loss $73.9M ($0.57/share) vs $40.4M ($0.35/share) in prior year; cash $330M funds ops into H2 2025.
- R&D expenses rose to $50.6M (from $28.4M) driven by IMVT-1402 development and batoclimab milestones.
- IMVT-1402 Phase 1 single-ascending dose data expected Sept 2023; multiple-ascending dose data Oct/Nov 2023.
- Batoclimab Phase 3 MG data H2 2024; Phase 3 TED data H1 2025; CIDP Phase 2b initial data H1 2024; GD proof-of-concept Q4 2023.
- Acquired IPR&D expenses $12.5M from batoclimab milestone achievement under HanAll agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000090/0001764013-23-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000090/imvt-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001764013-23-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer